Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
about
Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung CancerDocetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary studyA phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient.Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxelMulticenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck.Pemetrexed for the treatment of non-small-cell lung cancer.Treatment of advanced non small cell lung cancer.Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study.Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisDocetaxel-associated epiphora.A dose-schedule finding design for phase I-II clinical trialsSecond-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.New avenues for second-line treatment of metastatic non-small-cell lung cancer.Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.¹⁸F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay.Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer.Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma.Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer.
P2860
Q27015786-81D6008E-8E35-4B80-871E-F1655A5748ADQ33301768-AF522178-A7C1-4FD6-B40C-BBD94286F0B1Q33378865-D98B3D5D-8632-4387-BA60-39147A6F49C3Q33632656-0E5515FB-7048-481E-B62F-119A4BF06129Q34464827-3ABF8A0A-6C99-46DF-8577-7852B2A31028Q34623415-560BE2B6-E7AA-40C3-88B7-C72987C3D2BDQ35003631-9824EF97-2718-4EBD-B39B-C31D4DA89702Q35667817-BEDE7B31-E700-4A0B-82E2-E7EE4A72F80FQ35995493-DFE7E41B-3A7F-4C49-BE9F-63FA3771FB2DQ36040002-EBD6692D-2F05-4ABA-A15C-3CE2A981EDC7Q36484970-F923A824-4CAA-48F2-BAFF-8D1DDB36D233Q36561848-1CA12E4D-3D32-4205-8528-CECF4D941C38Q36609433-0564DE64-42E9-46BD-A70E-B2DE14402483Q36636822-2845505B-95C7-4FF0-9838-19BC406E85FAQ37030260-13C46273-F270-458B-8CB1-33B8418DA58DQ37135295-BDBF9B7F-FC32-43E0-9798-32E06FA0A303Q37205484-985E46BD-BF18-49D9-809A-EA147119E100Q37357304-59C969BF-2E1A-49C6-872A-21AC0188B57EQ37732287-1C8B072E-C6D9-495E-8EE9-B04A91814C79Q37744191-50A2DB58-04D2-4108-BB04-3DDA50A3DA93Q37909780-BC823C9E-5111-4BE4-9655-6EA8A34165C0Q37945643-B91BE471-AAD3-4CF1-B207-46EB466BC1D0Q37957744-B568DFDC-9724-461D-AB68-39E78B7CE90EQ38086122-07EBFB9D-7C3B-4B03-B17D-E5BB929F3F72Q40521965-08D477DC-9DCC-4165-8114-AC2345D55562Q41882527-3120781B-05E2-48DC-B884-144EF96546D0Q42984481-DC86DDDD-D835-419E-957B-451A66D7A413Q48340615-B7A75E17-511D-41D3-8F70-8592C4751089Q48623249-7872239D-ED8A-410B-B2F3-DFA1C8E5F2B7Q53065761-9B6C8AAC-F4CE-406F-B21B-380221AEACEAQ53567790-4BBE469C-AB9F-4B93-A391-D89C05282D2A
P2860
Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Phase II randomised trial comp ...... mall-cell lung cancer (NSCLC).
@en
Phase II randomised trial comp ...... ced non-small-cell lung cancer
@nl
type
label
Phase II randomised trial comp ...... mall-cell lung cancer (NSCLC).
@en
Phase II randomised trial comp ...... ced non-small-cell lung cancer
@nl
prefLabel
Phase II randomised trial comp ...... mall-cell lung cancer (NSCLC).
@en
Phase II randomised trial comp ...... ced non-small-cell lung cancer
@nl
P2093
P356
P1433
P1476
Phase II randomised trial comp ...... mall-cell lung cancer (NSCLC).
@en
P2093
A Ducolone
D Debieuvre
J Tredaniel
J-L Breton
P356
10.1093/ANNONC/MDI018
P577
2005-01-01T00:00:00Z